Member companies who are part of the ACS GCI Pharmaceutical Roundtable come together to catalyze innovative approaches to improving process efficiency and product quality through green chemistry and engineering. By working together, the Roundtable provides leadership and influence throughout the industry and supply chain. For example, the Pharmaceutical Roundtable has awarded over $2 million dollars in funding to further key research priorities for greener chemistries. In addition, the Roundtable continues to develop a valuable set of tools including a solvent selection guide, Process Mass Intensity/LCA calculator, and a powerful reagent guide.
The ACS GCI Pharmaceutical Roundtable invites all corporations meeting the definition of membership to consider joining. Companies are encouraged to join if they are committed to the integration of green chemistry and green engineering into the business of drug discovery and production.
The ACS GCI Pharmaceutical Roundtable welcomes the active participation of companies meeting the following eligibility descriptions:
Any corporation, or subsidiary, division or unit thereof, significantly engaged in the manufacture and marketing of finished dosage form ethical pharmaceutical or biological products under his or its own brand names for the cure, alleviation, mitigation, treatment, prevention or diagnosis of disease, and significantly engaged in pharmaceutical, biopharmaceutical or biological research and development of new molecular entities or new therapies, preventative, or in vivo diagnostics, or new systems of therapy, prevention, or diagnosis and who will continue to conduct such research and development.
Associate Membership Eligibility
Associates shall be corporations, or subsidiaries, divisions or units thereof, not eligible for membership under Members above, who are:
- Significantly engaged in research and development on their own behalf or as a provider of contract research and development services to companies meeting the definition of Member, directly related to the development or production of ethical pharmaceutical or biological products for the cure, alleviation, mitigation, treatment or prevention of disease.
- Significantly engaged in the manufacture of intermediates, active pharmaceutical ingredient, or finished dosage form ethical pharmaceutical or biological products.
Associates shall have all the rights, privileges and duties prescribed by the Business Plan, and such other rights, privileges and duties as the Management Team may from time to time establish by resolution, except the right to vote.
Affiliates shall be corporations, or subsidiaries, divisions or units thereof, not eligible for membership as Members or Associates above, who are:
- Engaged in research and development that significantly overlaps with ethical pharmaceutical, biopharmaceutical or biological research and development including but not limited to: agrochemicals, animal health, new modalities/technologies, scientific consumables, biomass, and metabolite production.
- Directly involved in the supply chain for the manufacture of ethical pharmaceutical or biopharmaceutical products such that pre-competitive collaboration within the green chemistry/green biopharma space would be mutually beneficially and result in an overall smaller environmental footprint.
Affiliates shall have all the rights, privileges and duties prescribed by the Business Plan, and such other rights, privileges and duties as the Management Team may from time to time establish by resolution, except the right to vote.
Membership fees are restricted for the purpose of meeting the project needs of the Roundtable. Annual fees range from $10,000 to $25,000 depending on company sales. Associate Member and Affiliate Member fees range from $5,000-$20,000 depending on company sales.